Abstracts

EVALUATION OF FDA-APPROVED RAPID HIV TESTS FOR LABORATORY DIAGNOSIS OF HIV INFECTION

The 2014 revised CDC/APHL Guidelines for Laboratory Diagnosis of HIV infection recommend that reactive antigen/antibody (ag/ab) screening tests be followed by a supplemental antibody test capable of differentiating HIV-1 from HIV-2. However, there is currently only one such supplemental test approved and available for use in the United States. We investigated the performance of other…

RECENCY STAGING OF HIV INFECTIONS THROUGH ROUTINE DIAGNOSTIC TESTING

Assay based staging of HIV for recency of infection has multiple purposes: at the population level, it enables cross-sectional incidence estimation. At the individual level, at diagnosis (as available in some national programmes and being contemplated in other large scale systems) recent/non-recent infection classification helps guide psychosocial support strategies, contact tracing, or inclusion in clinical…

DEVELOPMENT OF A HIGH-THROUGHPUT MULTIPLEX ASSAY FOR MEASURING HIV INCIDENCE

In order to assess the impact of HIV prevention strategies, it is critical to measure the rate at which new HIV infections are occurring in populations. To achieve needed performance requirements (e.g., long ‘mean duration of recent infection’ [MDRI], low ‘false recent rate’ [FRR]), most programs currently use multi-assay algorithms including avidity-modified antibody and viral…

IDENTIFYING RECENT HIV INFECTIONS: AN INDIVIDUALIZED ASSESSMENT OF RISK

The accurate identification of recent HIV infection remains an important area of research to inform population-based HIV prevention and treatment intervention policies. Methods that use cross-sectional testing and biomarker information might be an alternative to longitudinal testing, as combinations of serological and molecular methods can potentially provide a means to identify recent HIV infections. The…

QUALITY OF LIFE IMPROVEMENT DURING SECOND-LINE THERAPY IN RESOURCE-LIMITED SETTINGS

Health-related quality of life (QoL) improves on first-line antiretroviral therapy (ART). However, at first-line failure, we have previously described poorer QoL among people in resource-limited settings (RLS) with higher viral load (VL). Change in QoL after starting second-line ART in RLS has not been evaluated. ACTG A5273 was a randomized clinical trial of second-line ART…

PROMISING RESULTS OF DOLUTEGRAVIR + LAMIVUDINE MAINTENANCE IN ANRS 167 LAMIDOL TRIAL

Dolutegravir (DTG) is a potent INSTI with high genetic barrier. The once-daily (QD) DTG-3TC combination is attractive, both drugs being safe, highly efficient and convenient. ANRS 167 LAMIDOL trial is an ongoing open-label, single-arm, multicenter trial assessing the efficacy and tolerance of DTG (50mgQD) – 3TC (300mgQD) in HIV-1 virologically suppressed patients (Pts) on first…

ADVERSE DRUG REACTIONS AMONG PATIENTS RECEIVING SECOND-LINE ART IN SOUTH AFRICA

As first-line antiretroviral therapy (ART) programmes mature, an increasing number of patients are being switched to second-line regimens. Adverse drug reactions (ADRs) which result primarily from medicines toxicity and drug interactions may compromise the effectiveness of treatment programs through its potential impact on treatment adherence and retention. Understanding the timing and rate of ADRs among…